Processa Pharmaceuticals, Inc. (PCSA) Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount

Processa Pharmaceuticals, Inc. Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount

Processa Pharmaceuticals, Inc. (PCSA) reported Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount of $1.42 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.

Financial Statements › Expense Statement › Income Tax

us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance · last filed 2026-03-18

• Processa Pharmaceuticals, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2025 was $1.42M, a 37.13% decline from fiscal 2024.
• Processa Pharmaceuticals, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2024 was $2.26M.
• Processa Pharmaceuticals, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2021 was $2.95M, a 0.89% decline from fiscal 2020.
• Processa Pharmaceuticals, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2020 was $2.97M, a 344.93% increase from fiscal 2019.